Gene Mapping Gives Rise To Drugs That Rebuild Tissue

The logical outcome of gene mapping is nigh. Biotechnology companies are using genetic information to design new drugs that may go beyond merely slowing or stopping a disease process to inducing the regeneration or repair of damaged tissue. Looking past the conventional drug targets of enzymes and gene-coupled receptors, researchers are seeking out molecules in the pathways along which biochemical signals are transferred. In some cases, their work has led to compounds--now in clinical trials or

Written bySteve Bunk
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

The groundwork for these advances has been laid over recent years by genetic mapping--the arrangement of mutable sites on a chromosome as deduced from genetic recombination experiments. This mapping has revealed remarkable similarities, or conservation, in the genes of a few organisms up and down the evolutionary tree. By altering genes from conserved areas of the genome in such organisms as yeast, nematode worms, fruit flies, zebra fish, mice, and cats, developmental biologists are elucidating the biochemical pathways and are finding new points of intervention for drugs to treat humans.

Photo: Exelixis FLY MODEL: Researchers at Exelixis Pharmaceuticals insert a human disease gene in the eye of a fruit fly to investigate the signaling pathway as a normal eye (left), degenerates into a "rough" eye. "Mass genetic mapping has put a library of just about all the known genes into the public domain," notes Geoffrey Duyk, chief scientific officer of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies